Novem Group Has $863,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Novem Group raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 31.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,361 shares of the biopharmaceutical company’s stock after buying an additional 323 shares during the period. Novem Group’s holdings in Regeneron Pharmaceuticals were worth $863,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of REGN. Capital International Investors boosted its position in Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $802,036,000. GAMMA Investing LLC raised its stake in shares of Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock worth $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock valued at $1,485,527,000 after buying an additional 810,144 shares during the last quarter. Finally, Amundi grew its stake in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after buying an additional 487,489 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating on the stock in a research report on Monday, June 2nd. Guggenheim restated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Bank of America decreased their price objective on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a report on Thursday, April 17th. Citigroup cut their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a “buy” rating on the stock in a report on Monday, June 2nd. Finally, Argus cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $822.58.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $545.00 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The firm has a fifty day moving average price of $550.54 and a two-hundred day moving average price of $627.29. The company has a market cap of $58.84 billion, a PE ratio of 13.87, a price-to-earnings-growth ratio of 2.01 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the company posted $9.55 EPS. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.65%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.